Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsBy Nathan Reiff. Originally Published: 3/12/2026. 
Key Takeaways - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is projected to surge to $366 billion over the next eight years. Many companies pursue niche strategies, developing medicines targeted at specific cancer types with specialized mechanisms. Fortunately, several promising treatments have shown strong potential—and with that comes the possibility of significant sales. Two smaller biotech companies are seeing substantial share-price momentum thanks to their leading oncology medicines. Beyond their therapeutic promise, these drugs could help their developers move toward greater stability and, eventually, profitability. That said, both companies remain typical biotech investments: high-risk ventures that also carry the potential for outsized rewards for investors willing to accept the uncertainty. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Decades ago, Washington sold the American public on ditching cash for credit cards to protect us from theft and stop criminals, but instead of stopping crime, it gave the government an unprecedented window into our daily lives—every flight, restaurant, and gallon of gas leaving a permanent data trail. Through a new initiative outlined in Federal Reserve Docket No. OP-1670, known as FedNow, the government is rolling out the ultimate financial tracking web that routes all those fragmented private transactions through a single centralized hub operated by the Federal Reserve itself, giving the federal government real-time 24/7 visibility into virtually every dollar moving through the U.S. economy with the power to flag or freeze your money with a single keystroke. Get the 4 steps to Fed-proof your savings now Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, rising nearly 37% in a week when the S&P 500 slipped about 1%. That added to a strong year-to-date (YTD) performance that has seen shares more than double. Still, with a consensus price target of $8.88, Wall Street appears to expect more—that target implies roughly 71% additional upside from current levels. The main catalyst for Iovance's move is its lead therapy, Amtagvi, a T‑cell immunotherapy for certain melanomas. Amtagvi has been approved in the United States since 2024 and is gaining momentum in sales, with additional approvals likely in the E.U., U.K., and other regions. When administered with Proleukin, the company's IL‑2 immunotherapy, management believes Amtagvi could reach over $1 billion in peak U.S. sales. Amtagvi's potential extends beyond melanoma: the FDA granted Fast Track Designation for the treatment of non‑small cell lung cancer, and the drug may be effective against other tumor types as well. Iovance's recent outperformance was also helped by its Q4 2025 earnings report in late February, which showed a smaller-than-expected loss per share and $5 million in revenue. For the full year, revenue rose roughly 30% year over year. That said, Iovance remains a small-cap biotech (about $2 billion) and is still treated as a higher-risk, penny-stock‑type name by some investors. Analyst sentiment is mixed—about half of its roughly a dozen ratings are Hold or Sell. Risks include the typical uncertainties of smaller drug developers and specific challenges tied to Amtagvi's manufacturing. Because the therapy is personalized, it is costly and complex to produce, which could limit profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) declined about 20% in March, but its year-to-date returns dwarf Iovance's: IBRX is up nearly 300% in 2026. Analysts' consensus price target of $13.60 implies roughly 70% upside from the stock's current price, even after the recent run-up. ImmunityBio's primary growth driver is Anktiva, a treatment for certain bladder cancers. In February, shares jumped after the E.U. regulator granted the drug conditional marketing authorization—the latest in a string of approvals worldwide. Anktiva is already driving revenue growth, with the company reporting $113 million in sales last year, a roughly 700% year-over-year increase. Like Amtagvi, Anktiva may have potential in other cancer types, and ImmunityBio is actively exploring additional indications. Despite the dramatic stock gains, IBRX remains a speculative investment. The company reported a full-year net loss of $351 million for 2025 as R&D expenses continue to mount. Wall Street appears somewhat more bullish on ImmunityBio than on Iovance—six of seven analysts rate the stock a Buy or equivalent—but significant execution and clinical risks remain.
| 
